Navigation Links
Endologix Receives Nasdaq Letter on Director Independence

IRVINE, Calif., June 12 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, today announced that on June 12, 2009, the Company received written notification from Nasdaq that the Company was no longer in compliance with Marketplace Rule 4350(c), which addresses independent director requirements.

In order to meet the requirements of this rule, the Company must maintain a board which is comprised of a majority of independent directors. Following the Company's Annual Meeting of Shareholders on June 11th, 2009, the current board composition reflects three independent and three non-independent directors. Consistent with Marketplace Rule 4350(c) (1), Nasdaq will provide the company a cure period in order to regain compliance until the earlier of the Company's next annual shareholders' meeting or June 11, 2010.

The Company is currently engaged in a search for a new independent director and fully expects to fulfill Nasdaq's independent director requirements within the allotted cure period.

The Company must submit to Nasdaq documentation, including biographies of any new directors, evidencing compliance within the allotted cure period. In the event the Company does not regain compliance within this cure period, Nasdaq rules require Staff to provide written notification to the Company that its securities will be delisted. At that time, the Company may appeal the delisting determination to a Listing Qualifications Panel.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at

Except for historical information contained herein, this news release contains forward-looking statements, specifically with respect to the fulfillment of Nasdaq independent director requirements, which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding risks and other factors that may cause actual results to differ materially from those expressed or implied.

    Endologix, Inc.                      The Ruth Group
    John McDermott, CEO                  Nick Laudico (646) 536-7030
    (949) 595-7200                       Zack Kubow (646) 536-7020

SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
2. Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service
3. Western Governors University Nursing Education Program Receives $500,000 Grant from the Texas Workforce Commission
4. Oncology Program at Texas Health Dallas Receives Outstanding Achievement Award
5. SeprOx Receives Texas Emerging Technology Fund Award
6. SHPS Receives Re-Accreditation from URAC for Multiple Health Management Programs
7. Herley Receives a $1.2 Million Contract Award for Complex Integrated Microwave Assemblies for U.S. Electronic Attack Aircraft
8. Elder Care Expert Doctor Marion Receives Accolades from Lehman College, Mature Market Resource Center in Same Week
9. Medifocus, Inc. receives Authorization Approval from Health Canada to launch its pivotal Phase III clinical study of focused microwave heating for treatment of breast cancer in Canada
10. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
11. MedApps Receives FDA Clearance on a New Way to Bring Cost-Effective Remote Health Monitoring to More People
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology: